Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma
Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorKite, A Gilead Company
About this trial
The goal of this clinical study is to learn more about the safety and effectiveness of the study drugs, KITE-363 and KITE-753, in participants with relapsed and/or refractory B-cell lymphoma.
Eligibility criteria
Qualifiers
Relapsed and/or refractory B-cell lymphoma (R/R BCL).
At least 1 measurable lesion.
Adequate organ and bone marrow (BM) function.
Disqualifiers
History of malignancy other than nonmelanoma skin cancer or carcinoma in situ (eg, cervix, bladder, or breast) unless disease free and without anticancer therapy (with the exception of hormonal therapy in the case of breast cancer) for at least 3 years.
History of allogeneic stem cell transplant (allo-SCT).
Auto-SCT within 6 weeks before the planned KITE-363 or KITE-753 infusion.
Presence of fungal, bacterial, viral, or other infection that is uncontrolled or requires intravenous (IV) antimicrobials for management.
Trial design
Treatments tested in this trial
- Cyclophosphamide
- Fludarabine
- KITE-363
- KITE-753
Treatment groups
247 Participants
are divided into 3 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov